Recruitment of an interferon molecular signaling complex to the mitochondrial membrane: Disruption by hepatitis C virus NS3-4A protease

Biochemical Pharmacology

Volumn 72, Issue 11, 2006, Pages 1477-1484

  Hiscott, John ^a   Lacoste, Judith ^a   Lin, Rongtuan ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Hepatitis C; Interferon; IRF; RIG I; Viral evasion

Indexed keywords

CILUPREVIR; I KAPPA B KINASE; I KAPPA B KINASE EPSILON; INTERFERON; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 3 4A; PROTEIN; PROTEIN CARDIF; PROTEINASE; PROTEINASE INHIBITOR; RNA HELICASE; UNCLASSIFIED DRUG; VX 950;

ANTIVIRAL ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; CONFOCAL MICROSCOPY; CYTOPLASM; HEPATITIS C; HEPATITIS C VIRUS; IMMUNE RESPONSE; INNATE IMMUNITY; MITOCHONDRIAL MEMBRANE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; HEPACIVIRUS; HUMANS; INTRACELLULAR MEMBRANES; MITOCHONDRIA; MULTIPROTEIN COMPLEXES; SIGNAL TRANSDUCTION; VIRAL NONSTRUCTURAL PROTEINS;

EID: 33750508963     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.06.030     Document Type: Article

References (69)

1. Aizaki H., Saito S., Ogino T., Miyajima N., Harada T., Matsuura Y., et al. Suppression of interferon-induced antiviral activity in cells expressing hepatitis C virus proteins. J Interferon Cytokine Res 20 (2000) 1111-1120
2. Akira S., and Takeda K. Toll-like receptor signalling. Nat Rev Immunol 4 (2004) 499-511
3. Alexopoulou L., Holt A.C., Medzhitov R., and Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413 (2001) 732-738
4. Andrejeva J., Childs K.S., Young D.F., Carlos T.S., Stock N., Goodbourn S., et al. The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter. Proc Natl Acad Sci USA 101 (2004) 17264-17269
5. Au W.C., Moore P.A., LaFleur D.W., Tombal B., and Pitha P.M. Characterization of the interferon regulatory factor-7 and its potential role in the transcription activation of interferon A genes. J Biol Chem 273 (1998) 29210-29217
6. Battaglia A.M., and Hagmeyer K.O. Combination therapy with interferon and ribavirin in the treatment of chronic hepatitis C infection. Ann Pharmacother 34 (2000) 487-494
7. Biron C.A. Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections. Semin Immunol 10 (1998) 383-390
8. Blight K.J., McKeating J.A., Marcotrigiano J., and Rice C.M. Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol 77 (2003) 3181-3190
9. Bonnard M., Mirtsos C., Suzuki S., Graham K., Huang J., Ng M., et al. Deficiency of T2K leads to apoptotic liver degeneration and impaired NF-kappaB-dependent gene transcription. EMBO J 19 (2000) 4976-4985
10. Breiman A., Grandvaux N., Lin R., Ottone C., Akira S., Yoneyama M., et al. Inhibition of RIG-I-dependent signaling to the interferon pathway during hepatitis C virus expression and restoration of signaling by IKKepsilon. J Virol 79 (2005) 3969-3978
11. Chen S.H., and Tan S.L. Discovery of small-molecule inhibitors of HCV NS3-4A protease as potential therapeutic agents against HCV infection. Curr Med Chem 12 (2005) 2317-2342
12. Chisari F.V. Unscrambling hepatitis C virus-host interactions. Nature 436 (2005) 930-932
13. Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., and Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244 (1989) 359-362
14. Fitzgerald K.A., McWhirter S.M., Faia K.L., Rowe D.C., Latz E., Golenbock D.T., et al. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 4 (2003) 491-496
15. Fitzgerald K.A., Rowe D.C., Barnes B.J., Caffrey D.R., Visintin A., Latz E., et al. LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll adapters TRAM and TRIF. J Exp Med 198 (2003) 1043-1055
16. Foy E., Li K., Sumpter Jr. R., Loo Y.M., Johnson C.L., Wang C., et al. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signalling. Proc Natl Acad Sci USA 79 (2005) 2689-2699
17. Gale Jr. M., Blakely C.M., Kwieciszewski B., Tan S.L., Dossett M., Tang N.M., et al. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol 18 (1998) 5208-5218
18. Gale Jr. M., and Foy E.M. Evasion of intracellular host defence by hepatitis C virus. Nature 436 (2005) 939-945
19. Gale Jr. M.J., Korth M.J., Tang N.M., Tan S.L., Hopkins D.A., Dever T.E., et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230 (1997) 217-227
20. Ghosh A.K., Majumder M., Steele R., Yaciuk P., Chrivia J., Ray R., et al. Hepatitis C virus NS5A protein modulates transcription through a novel cellular transcription factor SRCAP. J Biol Chem 275 (2000) 7184-7188
21. Ghosh A.K., Steele R., Meyer K., Ray R., and Ray R.B. Hepatitis C virus NS5A protein modulates cell cycle regulatory genes and promotes cell growth. J Gen Virol 80 Pt 5 (1999) 1179-1183
22. Goudreau N., and Llinas-Brunet M. The therapeutic potential of NS3 protease inhibitors in HCV infection. Expert Opin Investig Drugs 14 (2005) 1129-1144
23. Hemmi H., Takeuchi O., Sato S., Yamamoto M., Kaisho T., Sanjo H., et al. The roles of two IkappaB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection. J Exp Med 199 (2004) 1641-1650
24. Iwasaki A., and Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 5 (2004) 987-995
25. Kang D.C., Gopalkrishnan R.V., Wu Q., Jankowsky E., Pyle A.M., and Fisher P.B. mda-5: an interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties. Proc Natl Acad Sci USA 99 (2002) 637-642
26. Kato H., Sato S., Yoneyama M., Yamamoto M., Uematsu S., Matsui K., et al. Cell type-specific involvement of RIG-I in antiviral response. Immunity 23 (2005) 19-28
27. Kawai T., Takahashi K., Sato S., Coban C., Kumar H., Kato H., et al. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol 6 (2005) 981-988
28. Kiyosawa K., Sodeyama T., Tanaka E., Gibo Y., Yoshizawa K., Nakano Y., et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 12 (1990) 671-675
29. Lamarre D., Anderson P.C., Bailey M., Beaulieu P., Bolger G., Bonneau P., et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426 (2003) 186-189
30. Levy D.E. Whence interferon? Variety in the production of interferon in response to viral infection. J Exp Med 195 (2002) F15-F18
31. Li X.D., Sun L., Seth R.B., Pineda G., and Chen Z.J. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc Natl Acad Sci USA 102 (2005) 17717-17722
32. Lin R., Heylbroeck C., Genin P., Pitha P.M., and Hiscott J. Essential role of interferon regulatory factor 3 in direct activation of RANTES chemokine transcription. Mol Cell Biol 19 (1999) 959-966
33. Lin R., Heylbroeck C., Pitha P.M., and Hiscott J. Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome-mediated degradation. Mol Cell Biol 18 (1998) 2986-2996
34. Lin R., Lacoste J., Nakhaei P., Sun Q., Yang L., Paz S., et al. Dissociation of a MAVS/IPS-1/VISA/Cardif-IKKε molecular complex from the mitochondrial outer membrane by Hepatitis C virus NS3-4A proteolytic cleavage. J Virol 80 (2006) 6071-6083
35. Lin R., Mamane Y., and Hiscott J. Structural and functional analysis of interferon regulatory factor 3: localization of the transactivation and autoinhibitory domains. Mol Cell Biol 19 (1999) 2465-2474
36. Lindenbach B.D., Evans M.J., Syder A.J., Wolk B., Tellinghuisen T.L., Liu C.C., et al. Complete replication of hepatitis C virus in cell culture. Science 309 (2005) 623-626
37. Maniatis T., Falvo J.V., Kim T.H., Kim T.K., Lin C.H., Parekh B.S., et al. Structure and function of the interferon-beta enhanceosome. Cold Spring Harb Symp Quant Biol 63 (1998) 609-620
38. Marie I., Durbin J.E., and Levy D.E. Differential viral induction of distinct interferon-alpha genes by positive feedback through interferon regulatory factor-7. EMBO J 17 (1998) 6660-6669
39. McWhirter S.M., Fitzgerald K.A., Rosains J., Rowe D.C., Golenbock D.T., and Maniatis T. IFN-regulatory factor 3-dependent gene expression is defective in Tbk1-deficient mouse embryonic fibroblasts. Proc Natl Acad Sci USA 101 (2004) 233-238
40. Melen K., Fagerlund R., Nyqvist M., Keskinen P., and Julkunen I. Expression of hepatitis C virus core protein inhibits interferon-induced nuclear import of STATs. J Med Virol 73 (2004) 536-547
41. Meylan E., Curran J., Hofmann K., Moradpour D., Binder M., Bartenschlager R., et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437 (2005) 1167-1172
42. Miller K., McArdle S., Gale Jr. M.J., Geller D.A., Tenoever B., Hiscott J., et al. Effects of the hepatitis C virus core protein on innate cellular defense pathways. J Interferon Cytokine Res 24 (2004) 391-402
43. Moradpour D., Brass V., Bieck E., Friebe P., Gosert R., Blum H.E., et al. Membrane association of the RNA-dependent RNA polymerase is essential for hepatitis C virus RNA replication. J Virol 78 (2004) 13278-13284
44. Munshi N., Yie J., Merika M., Senger K., Lomvardas S., Agalioti T., et al. The IFN-beta enhancer: a paradigm for understanding activation and repression of inducible gene expression. Cold Spring Harb Symp Quant Biol (1999) 64
45. Perry A.K., Chow E.K., Goodnough J.B., Yeh W.C., and Cheng G. Differential requirement for TANK-binding kinase-1 in type I interferon responses to toll-like receptor activation and viral infection. J Exp Med 199 (2004) 1651-1658
46. Peters R.T., Liao S.M., and Maniatis T. IKKepsilon is part of a novel PMA-inducible IkappaB kinase complex. Mol Cell 5 (2000) 513-522
47. Pflugheber J., Fredericksen B., Sumpter Jr. R., Wang C., Ware F., Sodora D.L., et al. Regulation of PKR and IRF-1 during hepatitis C virus RNA replication. Proc Natl Acad Sci USA 99 (2002) 4650-4655
48. Pomerantz J.L., and Baltimore D. NF-kappaB activation by a signaling complex containing TRAF2, TANK and TBK1, a novel IKK-related kinase. EMBO J 18 (1999) 6694-6704
49. Rehermann B., and Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 5 (2005) 215-229
50. Rosenberg S. Recent advances in the molecular biology of hepatitis C virus. J Mol Biol 313 (2001) 451-464
51. Sato M., Hata N., Asagiri M., Nakaya T., Taniguchi T., and Tanaka N. Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7. FEBS Lett 441 (1998) 106-110
52. Sato M., Suemori H., Hata N., Asagiri M., Ogasawara K., Nakao K., et al. Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction. Immunity 13 (2000) 539-548
53. Sato M., Tanaka N., Hata N., Oda E., and Taniguchi T. Involvement of the IRF family transcription factor IRF-3 in virus-induced activation of the IFN-beta gene. FEBS Lett 425 (1998) 112-116
54. Servant M.J., Grandvaux N., and Hiscott J. Multiple signaling pathways leading to the activation of interferon regulatory factor 3. Biochem Pharmacol 64 (2002) 985-992
55. Seth R.B., Sun L., Ea C.K., and Chen Z.J. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 122 (2005) 669-682
56. Sharma S., tenOever B.R., Grandvaux N., Zhou G.P., Lin R., and Hiscott J. Triggering the interferon antiviral response through an IKK-related pathway. Science 300 (2003) 1148-1151
57. Song J., Fujii M., Wang F., Itoh M., and Hotta H. The NS5A protein of hepatitis C virus partially inhibits the antiviral activity of interferon. J Gen Virol 80 Pt 4 (1999) 879-886
58. Sumpter Jr. R., Loo Y.M., Foy E., Li K., Yoneyama M., Fujita T., et al. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol 79 (2005) 2689-2699
59. Tan S.L., and Katze M.G. How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A. Virology 284 (2001) 1-12
60. Taniguchi T., Ogasawara K., Takaoka A., and Tanaka N. Irf family of transcription factors as regulators of host defense. Annu Rev Immunol 19 (2001) 623-655
61. Taylor D.R., Shi S.T., Romano P.R., Barber G.N., and Lai M.M. Inhibition of the interferon-inducible protien kinase PKR by HCV E2 protein. Science 285 (1999) 107-110
62. Tojima Y., Fujimoto A., Delhase M., Chen Y., Hatakeyama S., Nakayama K., et al. NAK is an IkappaB kinase-activating kinase. Nature 404 (2000) 778-782
63. Wakita T., Pietschmann T., Kato T., Date T., Miyamoto M., Zhao Z., et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11 (2005) 791-796
64. Wasley A., and Alter M.J. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 20 (2000) 1-16
65. Wieland S.F., and Chisari F.V. Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol 79 (2005) 9369-9380
66. Xu L.G., Wang Y.Y., Han K.J., Li L.Y., Zhai Z., and Shu H.B. VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol Cell 19 (2005) 727-740
67. Yoneyama M., Kikuchi M., Natsukawa T., Shinobu N., Imaizumi T., Miyagishi M., et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 5 (2004) 730-737
68. Yoneyama M., Suhara W., Fukuhara Y., Fukada M., Nishida E., and Fujita T. Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300. EMBO J 17 (1998) 1087-1095
69. Zhong J., Gastaminza P., Cheng G., Kapadia S., Kato T., Burton D.R., et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 102 (2005) 9294-9299